Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.

When Eli Lilly's Lebanon campus is complete, it will manufacture several of the pharma's APIs and genetic medicines to serve US patients.

Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics to develop ORKA-001 using Hypercon Technology.

Citius Oncology has secured up to $36.5m to accelerate the commercialisation of Lymphir, a recombinant fusion protein immune therapy.

Pharmaceutical Technology rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.

MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).

Why does product loss occur in aseptic fill-finish, and how can a CDMO overcome material constraints to preserve as much drug product as possible?

Sunshine Lake Pharma, Lannett and its wholly owned subsidiary Lanexa Biologics have received FDA approval for Langlara.

Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.

Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies targeting wider patient groups.

As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.